Observational studyBMC pediatrics2025
"Characteristics of children with multisystem inflammatory syndrome in children during different COVID-19 waves "Single centre Study".
Observational study in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultisystem inflammatory syndrome in children (MIS-C) has been identified as a systemic inflammatory disorder complicating Coronavirus Disease 2019 (COVID-19) in children. Three different definition criteria have been proposed including clinical and laboratory features. MIS-C has variable presentation, severity and outcome. This study aimed to describe the clinic-laboratory and imaging features of MIS-C among Egyptian pediatric patients, as well as the treatment and outcome. PATIENTS AND
methodsThis was a retrospective observational study that included 142 MIS-C patients who were admitted at Children’s Hospital, Ain Shams University during the period from June 8, 2020, to January 26, 2022. Diagnosis of MIS-C followed CDC criteria. The medical records of the patients were reviewed for age, gender, initial presentation, interval time since COVID-19 infection or contact with COVID-19 patient, course of the disease, blood picture, acute phase reactants, kidney and liver function tests, imaging studies mainly echocardiogram and magnetic resonance imaging of the brain, therapeutic lines and outcome).
resultsThe median age varied from 4.5 years (4th wave) to 9 years (2nd wave). PCR positivity declined from 61% (1st wave) to 0% (4th wave), with lower IgG and higher IgM levels in the 1st wave (p < 0.001). Fever was universal (100%), Gastrointestinal symptoms were more common in the 1st wave (p = 0.005), whereas respiratory and neurological symptoms rose in later waves (p < 0.05). Lymphopenia and thrombocytopenia varied across waves (p < 0.01), with elevated inflammatory markers consistent throughout. Cardiac involvement, particularly coronary abnormalities, was highest in the 1st wave (p = 0.005). Treatment included IVIG and steroids, with increased use of pulse steroids and anti-IL1 therapy in later waves (p = 0.001). Hospital stays shortened from 10 days (2nd wave) to 3.5 days (4th wave), and mortality was highest in the 1st wave (9.4%). Conclusion: MIS-C cases in our center showed a consistent 2–7 weeks lag after COVID-19 peaks, with variable clinical and treatment trends. Improved outcomes over time, including shorter hospital stays and lower mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.